| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | BLLF1 |
| Uniprot No | P03200 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-493aa |
| 氨基酸序列 | MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFADPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPS |
| 预测分子量 | 54.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BLLF1重组蛋白的参考文献示例(注：部分文献信息为模拟概括，仅供参考)：
1. **"BLLF1 glycoprotein mediates Epstein-Barr virus entry into epithelial cells"**
*作者：H. M. Liu, J. T. Lin*
摘要：研究揭示了EBV的BLLF1重组蛋白通过结合宿主细胞表面受体介导病毒入侵上皮细胞的分子机制，证实其糖基化修饰对病毒感染性至关重要。
2. **"Expression and purification of recombinant BLLF1 in baculovirus system for antibody production"**
*作者：K. Tanaka, Y. Nakamura*
摘要：利用杆状病毒表达系统成功制备高纯度BLLF1重组蛋白，并验证其作为抗原用于EBV特异性中和抗体的高效诱导，为疫苗开发提供基础。
3. **"Structural analysis of BLLF1 reveals conserved epitopes for broad-spectrum EBV neutralization"**
*作者：R. S. Perez, M. A. Palser*
摘要：通过冷冻电镜解析BLLF1重组蛋白的三维结构，鉴定出跨EBV毒株保守的抗原表位，为设计广谱EBV疫苗提供结构生物学依据。
4. **"BLLF1-based virus-like particles elicit potent humoral immunity in animal models"**
*作者：L. Wang, G. F. Gao*
摘要：将BLLF1重组蛋白组装成病毒样颗粒(VLPs)，在小鼠模型中诱导高水平中和抗体，显著抑制EBV感染，展示其作为预防性疫苗的潜力。
*注：以上文献信息为模拟示例，实际研究中建议通过PubMed/Google Scholar以"BLLF1 recombinant protein"等关键词检索具体文献。*
**Background of BLLF1 Recombinant Protein**
BLLF1 is a glycoprotein encoded by the Epstein-Barr virus (EBV), a herpesvirus linked to infectious mononucleosis and several cancers, including Burkitt’s lymphoma and nasopharyngeal carcinoma. The BLLF1 gene product, gp350/220. is the most abundant glycoprotein on the viral envelope and plays a critical role in EBV’s entry into host cells. It mediates attachment by binding to complement receptor type 2 (CR2/CD21) on B lymphocytes and epithelial cells, facilitating viral tropism and initiation of infection.
Recombinant BLLF1 protein is produced through genetic engineering, often expressed in mammalian or insect cell systems to ensure proper post-translational modifications, such as glycosylation, which are essential for its structural and functional integrity. This engineered protein retains the key domains required for receptor interaction, making it a valuable tool for studying EBV pathogenesis, host-cell entry mechanisms, and immune responses.
Research applications include its use as a target for vaccine development. For instance, a gp350-based vaccine has shown promise in preclinical and early clinical trials by eliciting neutralizing antibodies that block viral attachment. Additionally, recombinant BLLF1 serves as an antigen in serological assays to detect EBV-specific antibodies, aiding diagnosis and epidemiological studies.
Beyond therapeutics, the protein is utilized to explore structural aspects of EBV glycoproteins, informing the design of antivirals and entry inhibitors. Its role in immune evasion, particularly in modulating B-cell activation and apoptosis, further underscores its relevance in understanding EBV persistence and oncogenesis.
Overall, BLLF1 recombinant protein is a pivotal resource in virology, bridging basic research and translational efforts to combat EBV-associated diseases.
×
